Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Fast Forward

Israel’s Largest Company Laying Off Half Its Israeli Workers

TEL AVIV (Reuters) – Israel-based Teva Pharmaceutical Industries will unveil a restructuring plan on Thursday that will include laying off more than half its Israeli workforce, the Calcalist financial news website said.

Teva’s plan includes closing its research and development center in the coastal city of Netanya, selling its logistics center in Shoham and cutting 3,300 jobs out of 6,430 in Israel, Calcalist said, citing people familiar with the matter.

Saddled with nearly $35 billion in debt since acquiring Allergan’s Actavis generic drug business for $40.5 billion, Teva made a series of changes after Kare Schultz joined as its new chief executive on Nov. 1.

A spokeswoman for Teva, the world’s largest generic drug maker which employs more than 56,000 people, declined to comment on Wednesday’s report, while Israeli Finance Minister Moshe Kahlon said only he was following the situation closely.

Meir Babayoff, chairman of the Negev region in the Histadrut labor federation, vowed to stop any layoffs and called on Israel’s government “to wake up,” but declined to detail what actions labor leaders plan pending an official announcement from Teva.

Teva said on Tuesday that Yitzhak Peterburg, who previously served as its chairman and interim CEO, had resigned from its board with immediate effect.

A message from our CEO & publisher Rachel Fishman Feddersen

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

We’ve set a goal to raise $260,000 by December 31. That’s an ambitious goal, but one that will give us the resources we need to invest in the high quality news, opinion, analysis and cultural coverage that isn’t available anywhere else.

If you feel inspired to make an impact, now is the time to give something back. Join us as a member at your most generous level.

—  Rachel Fishman Feddersen, Publisher and CEO

With your support, we’ll be ready for whatever 2025 brings.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at editorial@forward.com, subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.

Exit mobile version